Real World Effectiveness of Benralizumab in Severe Eosinophilic Asthma.

[1]  A. Nanzer,et al.  Real-World Effectiveness and the Characteristics of a 'Super-Responder' to Mepolizumab in Severe Eosinophilic Asthma. , 2020, Chest.

[2]  S. Korn,et al.  Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab , 2020, Drug Safety.

[3]  M. Humbert,et al.  Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma , 2019, Advances in Therapy.

[4]  D. Price,et al.  Characterization of severe asthma worldwide: data from the International Severe Asthma Registry (ISAR). , 2019, Chest.

[5]  J. Sohn,et al.  Increased mortality in patients with corticosteroid-dependent asthma: a nationwide population-based study , 2019, European Respiratory Journal.

[6]  P. Howarth,et al.  Randomised controlled trials in severe asthma: selection by phenotype or stereotype , 2018, European Respiratory Journal.

[7]  R. Buhl,et al.  Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature , 2018, European Respiratory Journal.

[8]  E. Bleecker,et al.  Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma , 2018, European Respiratory Journal.

[9]  K. Rabe,et al.  Efficacy and Safety of Dupilumab in Glucocorticoid‐Dependent Severe Asthma , 2018, The New England journal of medicine.

[10]  K. Rabe,et al.  Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma , 2017, The New England journal of medicine.

[11]  F. Albers,et al.  Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. , 2017, The Lancet. Respiratory medicine.

[12]  E. Bleecker,et al.  Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial , 2016, The Lancet.

[13]  W. Busse,et al.  Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial , 2016, The Lancet.

[14]  A. Zwinderman,et al.  The prevalence of severe refractory asthma. , 2015, The Journal of allergy and clinical immunology.

[15]  Ian D Pavord,et al.  Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.

[16]  E. Bleecker,et al.  International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma , 2013, European Respiratory Journal.

[17]  S. Wenzel,et al.  Dupilumab in persistent asthma with elevated eosinophil levels. , 2013, The New England journal of medicine.

[18]  G. Walsh.  Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions. , 2009, Current opinion in molecular therapeutics.

[19]  W. Busse,et al.  Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. , 2001, The Journal of allergy and clinical immunology.

[20]  G H Guyatt,et al.  Development and validation of a questionnaire to measure asthma control. , 1999, The European respiratory journal.

[21]  G. Guyatt,et al.  Development and validation of the Mini Asthma Quality of Life Questionnaire. , 1999, The European respiratory journal.